2024 Evexias / Farmakeio settlement
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as September 2024. Evidence tier: Documented record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
Evexias Medical Group and Farmakeio sued FDA over its 2023 placement of more than a dozen peptides in Category 2. In the September 2024 settlement FDA agreed to publish a Federal Register notice for two advisory committee meetings, on October 29 and December 4, 2024.
FDA’s final summary minutes record what followed. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding L-theanine (1-12), ibutamoren mesylate (1-13), ipamorelin free base and acetate (0-12 each) and kisspeptin-10 (0-11) to the 503A bulks list. On December 4, 2024 it voted against CJC-1295 free base (0-13), AOD-9604 (0-12) and thymosin alpha-1 free base (4-17), along with the related salt forms.
Evidence tier: Documented record.
Sources: Alliance for Pharmacy Compounding, settlement release, September 2024; FDA final summary minutes of the October 29, 2024 and December 4, 2024 committee meetings (archived copies of fda.gov/media/185412 and 185642).